What is the prevalence of Abetalipoproteinemia?

Abetalipoproteinemia is an ultra-rare genetic disorder with an estimated prevalence of less than 1 in 1,000,000 individuals worldwide. Because Abetalipoproteinemia is so infrequently diagnosed, exact incidence rates are not available, and it is likely that many cases remain undiagnosed or misattributed to other malabsorptive conditions.

How rare is Abetalipoproteinemia?

Abetalipoproteinemia is classified as an ultra-rare disease. Clinical literature suggests that fewer than 100 cases have been documented in medical reports globally. Due to the extreme rarity of Abetalipoproteinemia, it is difficult to establish precise epidemiological statistics, and the true number of affected individuals may be higher than those currently recorded in clinical databases.

Does Abetalipoproteinemia affect specific groups differently?

Research indicates that Abetalipoproteinemia does not show a predilection for one gender over the other; it affects males and females equally. While the condition has been reported across various ethnic populations, there is no evidence suggesting higher concentrations in specific geographic regions. Abetalipoproteinemia typically presents in early infancy, often within the first few months of life, as infants fail to thrive or exhibit gastrointestinal symptoms due to an inability to absorb dietary fats and fat-soluble vitamins.

What challenges exist in tracking Abetalipoproteinemia prevalence?

Accurate data collection for Abetalipoproteinemia is hindered by several factors:

• Underdiagnosis: Symptoms like failure to thrive or steatorrhea may be misdiagnosed as more common digestive or metabolic disorders.


• Lack of Awareness: Because of the ultra-rare nature of Abetalipoproteinemia, primary care providers may not screen for it unless specific neurological or visual symptoms emerge.


• Data Fragmentation: Rare disease registries, such as the community at DiseaseMaps.org, play a vital role in connecting the 19 registered members with Abetalipoproteinemia to provide a clearer, real-world picture of the patient experience that traditional clinical trials may miss.

Next steps

• Consult a metabolic specialist or a clinical geneticist for diagnostic testing if you suspect Abetalipoproteinemia.


• Join the Abetalipoproteinemia community at DiseaseMaps.org to connect with others sharing similar experiences.


• Ensure regular monitoring of fat-soluble vitamin levels (A, D, E, and K) with your healthcare team.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Abetalipoproteinemia.


• Orphanet: Rare Disease Database (ORPHA:10).


• Online Mendelian Inheritance in Man (OMIM): #200100 (Abetalipoproteinemia).


• Journal of Clinical Lipidology: Clinical management and prevalence of rare lipid disorders.